TY - JOUR
T1 - Impaired expression of protein phosphatase 2A subunits enhances metastatic potential of human prostate cancer cells through activation of AKT pathway
AU - Pandey, P.
AU - Seshacharyulu, P.
AU - Das, S.
AU - Rachagani, S.
AU - Ponnusamy, M. P.
AU - Yan, Y.
AU - Johansson, S. L.
AU - Datta, K.
AU - Lin, M. Fong
AU - Batra, S. K.
N1 - Funding Information:
This work was supported, in part, by grants from the Department of Defense (PC074289) and the National Institutes of Health (R01 CA138791). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
PY - 2013/6/25
Y1 - 2013/6/25
N2 - Background: Protein phosphatase 2A (PP2A) is a dephosphorylating enzyme, loss of which can contribute to prostate cancer (PCa) pathogenesis. The aim of this study was to analyse the transcriptional and translational expression patterns of individual subunits of the PP2A holoenzyme during PCa progression. Methods: Immunohistochemistry (IHC), western blot, and real-time PCR was performed on androgen-dependent (AD) and androgen-independent (AI) PCa cells, and benign and malignant prostate tissues for all the three PP2A (scaffold, regulatory, and catalytic) subunits. Mechanistic and functional studies were performed using various biochemical and cellular techniques. Results: Through immunohistochemical analysis we observed significantly reduced levels of PP2A-A and-Bγ subunits (P<0.001 and P=0.0002) in PCa specimens compared with benign prostate. Contemporarily, there was no significant difference in PP2A-C subunit expression between benign and malignant tissues. Similar to the expression pattern observed in tissues, the endogenous levels of PP2A-A and Bγ subunits were abrogated from the low metastatic to high metastatic and AD to AI cell line models, without any change in the catalytic subunit expression. Furthermore, using in vitro studies we demonstrated that PP2A-Aa scaffold subunit has a role in dampening AKT, β-catenin, and FAK (focal adhesion kinase) signalling. Conclusion: We conclude that loss of expression of scaffold and regulatory subunits of PP2A is responsible for its altered function during PCa pathogenesis.
AB - Background: Protein phosphatase 2A (PP2A) is a dephosphorylating enzyme, loss of which can contribute to prostate cancer (PCa) pathogenesis. The aim of this study was to analyse the transcriptional and translational expression patterns of individual subunits of the PP2A holoenzyme during PCa progression. Methods: Immunohistochemistry (IHC), western blot, and real-time PCR was performed on androgen-dependent (AD) and androgen-independent (AI) PCa cells, and benign and malignant prostate tissues for all the three PP2A (scaffold, regulatory, and catalytic) subunits. Mechanistic and functional studies were performed using various biochemical and cellular techniques. Results: Through immunohistochemical analysis we observed significantly reduced levels of PP2A-A and-Bγ subunits (P<0.001 and P=0.0002) in PCa specimens compared with benign prostate. Contemporarily, there was no significant difference in PP2A-C subunit expression between benign and malignant tissues. Similar to the expression pattern observed in tissues, the endogenous levels of PP2A-A and Bγ subunits were abrogated from the low metastatic to high metastatic and AD to AI cell line models, without any change in the catalytic subunit expression. Furthermore, using in vitro studies we demonstrated that PP2A-Aa scaffold subunit has a role in dampening AKT, β-catenin, and FAK (focal adhesion kinase) signalling. Conclusion: We conclude that loss of expression of scaffold and regulatory subunits of PP2A is responsible for its altered function during PCa pathogenesis.
UR - http://www.scopus.com/inward/record.url?scp=84879687996&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84879687996&partnerID=8YFLogxK
U2 - 10.1038/bjc.2013.160
DO - 10.1038/bjc.2013.160
M3 - Article
C2 - 23598299
AN - SCOPUS:84879687996
SN - 0007-0920
VL - 108
SP - 2590
EP - 2600
JO - British journal of cancer
JF - British journal of cancer
IS - 12
ER -